StemCell Therapy

TENDRING has been revealed to be one of the worst areas for sight loss in the country, according to the latest data from the NHS.

Opticians website Book An Eye Test has compiled a list of the Top 10 places in the UK in which people have the poorest eyesight.

Sight loss is defined as being full or partial loss of sight, and temporary or permanent blindness, in one or both eyes.

North Norfolk tops the lists, with 5.45 per cent of people living with sight loss, but Tendring has also crept into the list with nearly 7,200 people with sight loss.

This makes the district the 9th worst area in the country for sight loss, with 4.84 per cent of its 145,000 residents living with poor vision.

Commenting on the findings, Katie Memory, director and managing partner at Memory Opticians, believes the results are not surprising given the average age of residents.

She said: The research shows that the places with the highest levels of sight loss are mainly situated in rural or coastal areas.

This is not surprising, as these areas are typically home to ageing populations, who often show higher rates of sight loss compared to younger generations, as sight loss increases gradually as we get older.

This also explains why, at the other end of the scale, large cities with younger populations such as London and Manchester contain fewer people suffering from sight loss.

You can view the full list by visiting bookaneyetest.co.uk/post/britains-vision.

Original post:
Here's the worst place in Essex for sight loss - Clacton and Frinton Gazette

UpMarketResearch publishes a detailed report on Eyesight Test Equipment market providing a complete information on the current market situation and offering robust insights about the potential size, volume, and dynamics of the market during the forecast period, 2020-2026. This report offers an in-depth analysis that includes the latest information including the current COVID-19 impact on the market and future assessment of the impact on Global Eyesight Test Equipment Market. The report contains XX pages, which will assist clients to make informed decision about their business investment plans and strategies for the market. As per the report by UpMarketResearch, the global Eyesight Test Equipment market is projected to reach a value of USDXX by the end of 2026 and grow at a CAGR of XX% during the forecast period.

Get FREE Exclusive PDF Sample Copy of This Report: https://www.upmarketresearch.com/home/requested_sample/51303

The Eyesight Test Equipment market report also covers an overview of the segments and sub-segmentations including the product types, applications, and regions. In the light of this harsh economic condition as prompted by the COVID-19 outbreak, the report studies the dynamics of the market, changing competition landscape, and the flow of the global supply and consumption.

The report exclusively deals with key areas such as market size, scope, and growth opportunities of the Eyesight Test Equipment market by analyzing the market trend and data available for the period from 2020-2026. Keeping 2019 as the base year for the research study, the report explains the key drivers as well as restraining factors, which are likely to have major impact on the development and expansion of the market during the forecast period.

The report, published by UpMarketResearch, is the most reliable information as the study relies on a concrete research methodology focusing on both primary as well as secondary sources. The report is prepared by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the private and public companies.

The report, prepared by UpMarketResearch, is widely known for its accuracy and factual figures as it consists of a concise graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years. It uses statistical surveying for SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics.

Customize Report and Inquiry for the Eyesight Test Equipment market Report: https://www.upmarketresearch.com/home/enquiry_before_buying/51303

Furthermore, the scope of the growth potential, revenue growth, product range, and pricing factors related to the Eyesight Test Equipment market are thoroughly assessed in the report in a view to entail a broader picture of the market. The report also covers the recent agreements including merger & acquisition, partnership or joint venture and latest developments of the manufacturers to sustain in the global competition of the Eyesight Test Equipment market.

Competition Landscape:

The report covers global aspect of the market, covering

Global Eyesight Test Equipment market by Types:

PortableStationary

Global Eyesight Test Equipment market by Applications:

ChildrenAdults

Key Players for Global Eyesight Test Equipment market:

EyeNetraBhavana MDCEssilor InternationalAlcon Inc.HeineHeidelberg Engineering GmbHSeiko Optical Products Co. Ltd.Nidek Co. Ltd.Carl Zeiss AGHoya CorporationAbbott Medical Optics.Inc.Johnson & Johnson Vision Care.Inc.Shenzhen Certainn Technology

Avail the Discount on this report @ https://www.upmarketresearch.com/home/request_for_discount/51303

UpMarketResearch offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About UpMarketResearch:

UpMarketResearch (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsPhone No.: +1 909 545 6473Email [emailprotected]Website https://www.upmarketresearch.comAddress 500 East E Street, Ontario, CA 91764, United States.

The rest is here:
Eyesight Test Equipment Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | UpMarketResearch -...

Prevent Blindness launches new awareness campaign, "Screen Time-Out," to help reduce the risk of digital eye strain.

CHICAGO (PRWEB) October 21, 2020

In response to increased virtual activity during the coronavirus pandemic, Prevent Blindness, the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight, today launched Screen Time-Out, an awareness campaign to encourage Americans, especially parents of young children, to introduce regular screen breaks into their daily routines.

During work, school and even personal downtime, people spend as much as 12 hours a day in front of a digital screen. This amount of screen time exacerbates the risk of digital eye strain, also known as computer vision syndrome, especially for children whose eyes are still developing. Symptoms may include tired, burning or itching eyes, dry eyes, blurred vision and/or headache. The risk of digital eye strain has recently risen to a mounting level in the United States during the coronavirus pandemic, with 53 percent of respondents in a recent survey feeling burnout on screens over the last few months.

"At Prevent Blindness, we are concerned about people spending more and more time in front of our screens," said Jeff Todd, president and CEO of Prevent Blindness. "As an organization dedicated to ensuring everyone has a lifetime of healthy vision, the Screen Time-Out campaign is meant to educate people and reduce the risk of eye strain, starting with the youngest among us.

The Screen Time-Out campaign will live on social media Facebook, Instagram and Pinterest where device users are already spending a lot of their recreational screen time.

According to a recent survey of American eyecare professionals, 64 percent of respondents have seen an increase in patients having issues due to more screen time. Sixty-eight percent said they have seen those issues in both children and adults.

"Digital eye strain has been a rising modern threat to people of all ages, and it is linked to myriad issues, including eye development and nearsightedness," said Dr. Linda Chous, pediatric optometrist. "It is important now more than ever to be mindful of how much time we spend with screens and take steps to reduce the impact of digital eye strain."

To reduce eye strain, Prevent Blindness recommends children and adults take regular breaks using the 20-20-20 rule: every 20 minutes, shift eyes away from the screen to look at an object at least 20 feet away for at least 20 seconds.

Other tips to avoid eye strain from the American Academy of Ophthalmology include:

For more information about Screen Time-Out and Prevent Blindness, visit http://www.preventblindness.org/screen-time-out.

About Prevent BlindnessFounded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, or to make a contribution to the sight-saving fund, call 1-800-331-2020. Or, visit us on the Web at http://www.preventblindness.org or http://www.facebook.com/preventblindness.

Share article on social media or email:

More:
Prevent Blindness Encourages Everyone to Take a Screen Time-Out - PR Web

In Exosome Therapeutic Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and charts which eases the understanding of facts and figures. A proficient data and excellent forecasting techniques used in this report are synonymous with accurateness and correctness. Exosome Therapeutic Market report is a painstaking analysis of existing scenario of the market which covers several market dynamics. The market study of this global Exosome Therapeutic Market business report takes into consideration market attractiveness analysis where each segment is benchmarked based on its market size, growth rate & general attractiveness.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Here is the original post:
Exosome Therapeutic Market 2020-2026 || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc,...

High response rates were observed for patients with relapsed/refractory Hodgkin lymphoma treated with the combination of vorinostat and an mTOR inhibitor, according to findings published in Clinical Cancer Research.1

Although the majority of patients diagnosed with Hodgkin lymphoma are considered to be cured following first-line treatment with standard therapy, 5-year survival rates for those with relapsed/refractory disease following primary treatment can be as low as 30%.2

Despite US Food and Drug Administration (FDA) approvals of brentuximab, a CD30 antibody-drug conjugate, and the programmed cell death 1 (PD-1) inhibitors pembrolizumab and nivolumab for the treatment of patients with relapsed/refractory Hodgkin lymphoma, an unmet need remains for new therapies in this setting.

Based on prior preclinical and early clinical evidence supporting the potential efficacy of dual histone deacetylase (HDAC) and AKT/mTOR inhibition for those with relapsed/refractory Hodgkin lymphoma, the cohort of patients with heavily pretreated Hodgkin lymphoma enrolled in a nonrandomized, open-label, dose-escalation phase 1 study (ClinicalTrials.gov Identifier: NCT01087554) investigating the combination of vorinostat, an HDAC inhibitor, with an mTOR inhibitor in advanced cancer was expanded.

The rationale for such an approach was grounded in evidence implicating HDAC overexpression and associated aberrant gene expression in relapsed/refractory Hodgkin lymphoma, as well as a possible role for mTOR signaling as a pathway for resistance to HDAC inhibition in this setting.2,3

At baseline, the 40 patients included in this analysis were aged at least 18 years; the median patient age was 33 years. Regarding race/ethnicity, 55%, 27.5%, 12.5%, and 5% of these patients were White, Hispanic, Black, and Asian, respectively. Stage IV disease was present in 65% of patients, and Eastern Cooperative Oncology Group (ECOG) performance status was 0 (30%), 1 (50%), and 2 (20%). The median number of prior treatments was 5, with previous therapies including brentuximab vendotin, autologous hematopoietic stem cell transplantation (HSCT), and allogeneic HSCT in 97.5%, 65%, and 30% of patients, respectively.

None of these patients had received prior treatment with a PD-1 inhibitor.

Vorinostat, in combination with either siroliumus and everolimus, was administered to 22 and 18 patients, respectively.

For those patients treated with vorinostat plus siroliumus, the complete response (CR) and partial response (PR) rates were both 27%. At a median follow-up of 43.3 months, median progression-free survival (PFS) was 5.8 months.

In the subgroup receiving vorinostat plus everolimus, the CR and PR rates were 11% and 22%, respectively, and, at a median follow-up of 21 months, the median PFS was 4.8 months. A comparison of median PFS for those treated with either sirolimus or everolimus did not show a significant difference (P =.13)

Of note, responses were seen even in patients who received prior treatment with AKT or HDAC inhibitors, the study authors commented.

Regarding the safety of combination therapy with an HDAC and an mTOR inhibitor, the most commonly reported grade 3/4 adverse events (AEs) in the overall study population were neutropenia, thrombocytopenia, and anemia. However, while the frequencies of grade 4 neutropenia, thrombocytopenia, and anemia for those treated with sirolimus were 9%, 36%, and 0%, respectively, the corresponding rates were 0%, 11%, and 9% for the subgroup receiving everolimus. No treatment-related grade 5 AEs were reported.

In their concluding remarks, the study authors noted that combined HDAC and mTOR inhibition has encouraging activity in patients with relapsed and/or refractory Hodgkin lymphoma and warrants further investigation.

References

Continued here:
Promising, Early Results for Combined HDAC and mTOR Inhibition in Relapsed/Refractory Hodgkin Lymphoma - Cancer Therapy Advisor

DENVER A baby broken, inside the womb.

Most doctors gave little unborn Payton Calvillo any hope she would survive. But through strong faith and the help of a team of medical experts, she is thriving today.

"She's a complete miracle baby," said Payton's mother, Ahna Calvillo.

When Ahna was just five months pregnant, she was told her unborn baby would probably not survive birth.

"It was pretty much a death sentence from the beginning."

Payton's bones were breaking and bending inside the womb.

"She likely had a problem where she couldn't make alkaline phosphatase properly," explained Dr. Sunil Nayak, a pediatric endocrinologist at Rocky Mountain Hospital for Children.

Alkaline phosphatase is needed for bones to grow and strengthen and there was little anyone could do.

Nineteen different specialists were on hand for the C-section delivery

"They even asked us the question that morning, how far do you want us to go?" Ahna remembered. "'Do you want a ventilator on her?', you know, 'How far do you want us to prolong her life?' Our ultimate hope and goal was that she would come out and breathe on her own."

"She just came out screaming," said Ahna. "She came out crying. She breathed on her own right away. She was perfect."

Payton was diagnosed with hypophosphatasia, a disorder that weakens bones and was immediately placed on a new FDA-approved medicine.

"Here we are just one year later at one year of age and you see a dramatic difference in the shape," said Dr. Jared Riley, a pediatric orthopedic surgeon at Rocky Mountain Hospital.

Before the medicine, 75% of all patients died by the age of five.

Now there is a 97% chance Payton will live a normal life.

"My baby was broken and that's what I needed God to do was a miracle," said Ahna.

One was also treated with bone fragments and cultured osteoblasts, which are bone-forming cells.

"Cultured" refers to cells that are grown under specific conditions outside of the natural environment (the body) and within a laboratory.

Both patients showed significant, but incomplete improvement, although no more formal studies have been conducted.

Then, the drug teriparatide (parathyroid hormone 1-34) has been given "off-label" to several adults with HPP with metatarsal stress fractures or femoral pseudo fractures, resulting in healing.

The drug is not permitted for use in children.

More research is necessary to determine the long-term safety and effectiveness of teriparatide in the treatment of HPP.

Every year eight million babies are born with genetic disorders passed down from generation to generation.

Payton will stay on the new medication for the next few years and then doctors will re-evaluate whether she needs to continue.

Payton's family didn't even know they carried the problematic HPP gene until an ultrasound revealed it in their unborn baby.

After being genetically tested, Payton's mother and grandfather are positive.

Neither one has ever suffered from weak or broken bones.

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens atjim.mertens@wqad.comor Marjorie Bekaert Thomas atmthomas@ivanhoe.com.

Continued here:
YOUR HEALTH: Saving an unborn baby breaking apart in the womb - WQAD.com

Transparency Market Research (TMR) has published a new report titled, Autologous cell therapy Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the global autologous cell therapy market was valued at US$ 7.5 Bn in 2018 and is projected to expand at a CAGR of 18.1% from 2019 to 2027.

Overview

Request a PDF Brochure https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=715

Rise in Prevalence of Neurological Disorders & Cancer and Others to Drive Market

Request for Analysis of COVID19 Impact on Autologous Cell Therapy Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=715

Bone Marrow Segment to Dominate Market

Neurology Segment to be Highly Lucrative Segment

Buy Autologous Cell Therapy Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=715&ltype=S

Hospitals Segment to be Highly Lucrative Segment

North America to Dominate Global Market

Competitive Landscape

The global autologous cell therapy market is fragmented in terms of number of players. Key players in the global market include Pharmicell Co., Inc., Castle Creek Biosciences, Inc., Vericel Corporation, Lineage Cell Therapeutics, Inc., BrainStorm Cell Therapeutics, Caladrius Biosciences, Inc., Opexa Therapeutics, Inc., Regeneus Ltd., Takeda Pharmaceutical Company Limited., Sangamo Therapeutics, U.S. Stem Cell, Inc. and other prominent players.

More Trending Reports by Transparency Market Research

Genome Engineering Market https://www.prnewswire.com/news-releases/genome-engineering-market-to-clock-cagr-of-10-9-from-2019-to-2027-crispr-gene-edition-tools-present-sizable-revenue-streams-tmr-301073517

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read this article:
Autologous Cell Therapy Market is Anticipated to Expand at a CAGR of 18.1% from 2019 to 2027 - Eurowire

With the success of first vaccine to reach phase I clinical trial and turning out to be safe, well-tolerated, and capable of generating an immune response against the virus in humans, a lot of hope has been created with this vaccine. However, the research is still ongoing to develop novel therapeutic treatments that could aid infected patients in the meantime. One such growing area of interest is the use of cell therapy.

Cell Therapy: A Potential Treatment for COVID-19?

Cell therapies represent highly innovative therapeutic approaches that have revolutionized healthcare practices. Several studies from all over the world has proposed stem-cells based therapy, specifically mesenchymal stem cells, as a suitable remedial approach in the treatment of acute respiratory distress syndrome (ARDS), which is the leading cause of death in COVID-19 patients. Even though there are no approved cell therapy-based approaches for the prevention or treatment of COVID 19, however, many clinical trials have begun, and scientists are trying relentlessly to develop a therapeutic to treat this disease.

Companies Engaged in the Manufacturing of Cell Therapies

Presently, over 100 industry players and 60 non-industry players are involved in the manufacturing of cell therapies; of these, 52% have the required capabilities for manufacturing T-cell therapies.

Satta King

The Key Hubs of Cell Therapy Manufacturing

Majority of the industrial stakeholders (41%) are based in North America, followed by those based in Europe (31%) and the remaining in Asia Pacific. It is worth mentioning that within Asia Pacific, Japan (8) emerged as a popular hub for cell therapy manufacturers.

Demand for Cell Therapies (in terms of number of patients) is Anticipated to Grow at a CAGR of >21%, During 2019-2030

Given that advanced therapeutic medicinal products (ATMPs) is relatively a niche domain, the overall commercial demand for cell therapies is estimated to be more than 18,500 patients in 2019 and this value is likely to grow to close to 0.4 billion patients by 2030.

To get a detailed information on the key players, recent developments, capacity available, demand and the likely market evolution, visit this link

Cell Therapy: A Potential Treatment for COVID-19?

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

More:
Cell Therapy: A Potential Treatment for COVID-19? | Roots Analysis - The Think Curiouser

Careful, man, theres a beloved actor here.

Jeff Bridges revealed that he has lymphoma, which is the most common type of blood cancer. And this sobering news has spurred celebrities and fans to send their best wishes to the star best known for playing the Dude, the White Russiandrinking bowler and casual-wear icon from the Coen brothers 1998 cult classic, The Big Lebowski.

But the Dude abides, and Bridges suggested that his outlook looks just as promising.

As the Dude would say.. New S**T has come to light, tweeted Bridges, 70, on Monday. I have been diagnosed with Lymphoma. Although it is a serious disease, I feel fortunate that I have a great team of doctors and the prognosis is good.

Celebrities such as Cary Elwes, John Lithgow, Patricia Arquette and George Takei posted encouraging words and prayers to Bridges, who is the son of Lloyd and Dorothy Bridges, and has starred in more than 70 films including Starman, True Grit and The Last Picture Show. He won an Academy Award in 2010 for Crazy Heart, and was honored with the Cecil B. DeMille lifetime-achievement award during the 2019 Golden Globes.

And he is now one of the most high-profile cases of lymphoma, a cancer of the bodys infection-fighting lymphatic system that affects the blood and bone marrow. And more than 85,000 new cases of lymphoma are expected to be diagnosed in the U.S. this year, according to American Cancer Society data shared by the Leukemia & Lymphoma Society, with some 791,550 people currently living with lymphoma or in remission from the disease in the U.S.

Many different types of lymphoma exist, and Bridges did not share any more details about his diagnosis or treatment. But his disclosure is an opportunity to share more information about lymphoma, the risk factors and symptoms to be aware of, as well as treatment options.

What is lymphoma?

Lymphoma is a type of cancer that starts in cells that are part of the bodys immune system, specifically the lymphocytes, which are a type of white blood cell that fights germs. So these cancers can affect the blood and bone marrow, as well as the other tissues and organs that produce, store and carry white blood cells including the spleen.

Doctors still dont know what specifically causes lymphoma, but at some point a lymphocyte mutates and begins to reproduce rapidly. The mutated, abnormal cells live longer than the normal cells would, and in time, the diseased and ineffective lymphocytes outnumber the healthy cells, which causes the lymph nodes, liver and spleen to swell.

There are two main types of lymphoma, the CDC explains, including:

Hodgkin lymphoma (HL), which spreads in an orderly manner from one group of lymph nodes to another.

Non-Hodgkin lymphoma (NHL), which spreads through the lymphatic system in a non-orderly manner.

What are the symptoms?

Signs and symptoms of lymphoma may include:

These symptoms can be signs of other health conditions, of course, so its recommended that anyone experiencing them should see a doctor to determine the cause.

How is it treated?

There are many different types of lymphoma including 90 different types of non-Hodgkin lymphoma and treatment varies depending on the type and severity. Generally, lymphoma treatment involves chemotherapy, radiation therapy and immunotherapy medication. The Mayo Clinic, which is an international authority on lymphoma research, explains that the goal of treatment is to destroy as many cancer cells as possible to bring the disease into remission. A bone marrow or stem cell transplant may be performed in some cases to help rebuild healthy bone marrow after chemo and radiation has suppressed the diseased bone marrow.

Bridges didnt specify his own treatment, only saying that he is beginning treatment and will keep the public posted on his recovery.

Treatment can be very expensive, however, with almost 60% of patients covered by Medicare telling the Leukemia & Lymphoma Society in a 2019 study that they decided to delay or forego treatment, largely due to steep out-of-pocket costs. It noted that some traditional Medicare lymphoma patients getting anti-cancer therapy though infusions experienced out-of-pocket costs of more than $19,000 in their first year. And costs can extend two or three years beyond a blood cancer diagnosis.

Who is most at risk?

While children, teens and adults can all develop lymphoma, some types are more common in certain age groups. The CDC notes that rates of Hodgkin lymphoma are highest among teens and young adults (ages 15 to 39) as well as among older adults (ages 75 and older). But non-Hodgkin lymphoma becomes more common as people get older.

Men are also slightly more likely to develop lymphoma than women, the CDC adds, and white people are more likely than Black people to develop non-Hodgkin lymphoma.

Cases have also been more common in people who are immunocompromised, including those who take drugs to suppress their immune systems. And some infections such as HIV and the Epstein-Barr virus are also associated with an increased lymphoma risk.

And like many other cancers, family history has been linked with a higher risk of Hodgkin lymphoma.

What is the survival rate?

The good news is, Hodgkin lymphoma is now considered to be one of the most curable forms of cancer, according to the Leukemia & Lymphoma Society, with a five-year survival rate of 94.4% among patients younger than 45 at diagnosis. And the five-year relative survival rate for those with Hodgkin lymphoma more than doubled from 40% in whites in 1960 to 1963 (the only data available) to 88.5% for all races from 2009 to 2015.

And the five-year relative survival rate for people with non-Hodgkin lymphoma rose from 31% in whites from 1960 to 1963 (the only data available) to 74.7% for all races from 2009 to 2015.

Still, an estimated 20,910 Americans are expected to die from lymphoma this year, including 19,940 with non-Hodgkin lymphoma and 970 with Hodgkin lymphoma.

How does COVID-19 complicate things?

While the medical community is still learning about COVID-19, the general consensus is that people with cancer, who are in active cancer treatment or have previously been treated for cancer, may be at higher risk of severe illness and death if they get the coronavirus. So its important that these folks lower their risk of exposure to COVID-19 by avoiding large crowds and non-essential travel; working from home, if possible; staying at least six feet away from people outside their household; wearing a face mask when they cant socially distance; as well as washing their hands frequently, and not touching their eyes, nose or mouth.

Where can I find more information or support?

Visit the CDC and American Cancer Society pages on lymphoma.

The Mayo Clinic also outlines its lymphoma research and treatment strategies on its website.

The Leukemia & Lymphoma Society and the Lymphoma Research Foundation also provide valuable information and support.

See original here:
Jeff Bridges is one of the 85,000-plus lymphoma cases expected in the U.S. this year - MarketWatch

New guidelines from he American Society of Hematology (ASH) for treating newly diagnosed acute myeloid leukemia (AML) in older patients recommend intensive antileukemic therapies over more conservative approaches, such as less-intensive therapies or supportive care, when treatment is considered tolerable.1

The guideline panel included physicians based in the United States and Canada who represented a variety of subspecialties including frailty, geriatric oncology, and patient-reported outcomes. In an interview with Targeted Therapies in Oncology, primary guidelines author Mikkael A. Sekeres, MD, MS, said the panel selection process was sensitive to gender and geographic distribution and included 3 leaders of cooperative groups in the United States for leukemia, as well as one from the National Cancer Institute of Canadas leukemia group.

These are the first guidelines published by ASH for any hematological malignancy. They are unique in how rigorously developed they were, [as they were] based on stringent standards for guideline development, said Sekeres, a professor in the Department of Medicine at Case Western Reserve University School of Medicine as well as medical director of the Clinical Trials Unit at Taussig Cancer Institute of Cleveland Clinic, both in Ohio.

In weighing multifactorial risks and benefits of initiating potential antileukemic therapy in patients with AML older than aged 65 years, decisions to pursue treatment may be influenced by the physicians or patients reluctance to assume an aggressive treatment strategy. The health care system also may contribute to poor prognoses in this patient subset due to treatment reluctance, as more than half of patients in this AML subgroup received no therapy and were not provided equal access to allogenic transplant once achieving remission.1 Because survival rates for this vulnerable population remain historically low, data regarding best practices are limited.

Methods for Determining Recommendations The recommendations were developed through a systemic review of evidence using the McMaster University Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach, allowing the panel to provide recommendations that vary in strength based on certainty of evidence available. Strong to conditional recommendations were based on investigator-assessed certainty of evidence available.1

Patient data included in the review were from patients with newly diagnosed de novo, treatment-related, and secondary AML aged 55 years or older with receipt of less-intensive or intensive antileukemic therapy and treated as part of a clinical trial with 20 or more patients. Patient data from those with acute promyelocytic leukemia, myeloid neoplasms associated with Down syndrome, and studies in which more than 75% of the population did not meet criteria for inclusion were excluded from the review.1

The data reviewed by the panel showed a limited number of randomized studies available for this population. Although a number of retrospective data studies were examined, Sekeres pointed out the potential for high selection bias in [such] studies due to factors like existing serious comorbidities, such as end-stage lung cancer. We made recommendations at different levels based on the quality of supporting data, couching our recommendations in the quality of data that we had, he said, adding that critical outcome factors such as caregiver burden, quality-of-life (QOL) impairment, functional status impairment, and severe toxicity also factored in to the panels decisions. The weight of these factors varied slightly with each clinical question. Sekeres said the panel tailored factors they considered relevant in managing an older adult with AML to each specific clinical question. Unfortunately, often due to poor health or functional status within this population, patients did not participate directly in providing this data.

Although the panel began with approximately 20 clinical questions, Sekeres said they narrowed down the guidelines to 6 key areas of consideration. Clinical questions were determined and prioritized by the panel and are shown below with corresponding recommendations.

With strong evidence based on moderate certainty provided by the clinical data, the panel recommends offering antileukemic therapy to patients over best supportive care whenever possible. The comparison of intensive therapy versus best supportive care suggests a hazard ratio for death of 0.36 (95% CI, 0.26-0.50) based on low quality of evidence.

This recommendation may seem incredibly obvious, but when you examine the data in the United States, you realize that a lot of older adults with AML are told to get their affairs in order and seek no treatment, said Sekeres. Lets be clear at the very beginning. If someone wants treatment, you should treat them, and this should be done in alignment with their overall QOL goals.

Level of evidence is of a lower certainty based on the data available, but the panel favors intensive therapybut placed a conditional recommendation on this determination. A review suggested that intensive therapy may produce a lower risk of death versus the alternative (HR, 0.78; 95% CI, 0.69-0.89) and that the risk of death may be lower at 1 year with this strategy (risk ratio [RR], 0.93; 95% CI, 0.85-1.01).1 The [limited available] studies support more intensive antileukemic therapy if it is consistent with the patients individual goals, Sekeres said. That involves the careful balance of potential benefit in terms of getting into remission and survival versus risks of dying. The risks to QOL and of being hospitalized for the first 4 to 6 weeks of diagnosis also weigh heavily on the decision-making process.

Sekeres said certain patients who receive one therapy and achieve remission still need additional intervention. [Remission] is not enough. You need to give more [treatment] or else the chances of long-term survival diminish, he said. Moderate quality evidence supports consolidation therapy for lower mortality (RR, 0.96; 95% CI, 0.89-1.03), longer survival times by a median of 3 months, and longer time to recurrence by a median of 1 month versus no consolidation.

We only know this through indirect evidence. Long-term survivors who are older always receive more than one course of chemotherapy, but there are no randomized trials stating that more...is better than just one course [of treatment] or that a certain number of courses is the ideal amount, Sekeres said. As such, the panel suggests treating patients who are not candidates for allogeneic hematopoietic stem cell transplantation with at least 2 cycles of intensive antileukemic therapy based on low certainty of evidence.

Considering potential treatment planning factors such as age, comorbidities, and patient goals can sometimes lead to a third branch of decision-making for older patients, Sekeres said. For example, some patients with AML are under the initial impression that they likely have 2 options for treatment: intense chemotherapy or no treatment with supportive care only. Sekeres explained that less-intensive therapy is a third option to strongly consider when trying to align care with the patients goals and life experiences. In the United States, this commonly includes hypomethylating agents azacitidine and decitabine.

As such, recommendation 4 is divided into 2 subgroups focusing on less-intensive therapy options using hypomethylating agents. There doesnt seem to be one preference for one hypomethylating agent over another or over other low-dose approaches, said Sekeres. As our guidelines were breaking, we knew of some trials that were going to be published that looked at combination therapy versus monotherapy.

In a phase 1/2 study (NCT02203773) reviewed by the ASH panel, azacitidine plus venetoclax (Venclexta) demonstrated a promising efficacy rate with a tolerable safety profile versus administrations of azacitidine alone. However, the patients in this positive study were subjected to required hospitalization to receive the combination therapy.2 In this case, if you think back to where we started regarding patient goals, you are now mixing goals, Sekeres said. If a patient wants a less-intensive approach, they typically want out of the hospital and to be at home.

As such, the official recommendation from the panel suggests the use of either a hypomethylating agent or low-dose cytarabine as monotherapy based on moderate certainty of evidence in patients who are not eligible for intensive regimens. The second part of the recommendation suggests favoring monotherapy over combination therapy. However, if the patient chooses to move forward with combination treatment, low-dose cytarabine plus glasdegib (Daurismo) or a hypomethylating agent plus venetoclax can be used based on randomized trial data.

A conditional recommendation based on a low level of certainty led to the panel suggesting continuous therapy versus a time-limited approach.

Sekeres said that although this recommendation had limited supporting evidence, the specific amount of time is somewhat irrelevant. [Patients] should continue to receive [the treatment] as long as they are responding, he said. There is currently no study that stops this therapy at a certain point.

The last recommendation is a favorite of Sekeres because this is where we make the very clear statement that if a patient wants blood transfusions while on hospice, that person should be allowed to do so. We consider it to be supportive care and not heroic, he said.

Sekeres also explained the importance of finding a less-intensive approach for patients who have concerns about the effects of intensive therapy but still desire treatment, perhaps because of an expressed wish to live long enough for an upcoming family celebration or other personal reasons. Concerns such as hospitalization time, tolerability, potential adverse effects, overall QOL, and functional status are all incredibly important factors to consider when deciding the best course of action. In some instances, it may be more important to focus on tolerability than overall survival in this fragile population.

The ASH guidelines are not intended to serve or be construed as a standard of care, said Sekeres, but they are intended to assist physicians and educate patients in making decisions about potential diagnostic and treatment alternatives.1 The data herein highlight an unmet need for continued advocacy and research.

Sekeres said his interest in this patient population and corresponding research focus began during his fellowship, where he felt that a set of guidelines were important to address this clinical question with evidence-based treatment support for newly diagnosed AML.

This is an extremely vulnerable population for whom the treatment decision at the very beginning of diagnosis is far from straightforward, Sekeres said. My job is somewhat easy because my decision trees dont have a lot of branches to them. However, its hard because the therapy we are giving has an appreciable mortality itself.

To provide fellow treating physicians with a key takeaway, Sekeres advised, Your most important job as a health care provider working with a patient who has leukemia is making sure you are helping that person identify what his or her goals are and then meeting those goals with the treatments that you are offering.

References:

1. Sekeres MA, Guyatt G, Abel G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020;4(15):3528-3549. doi:10.1182/bloodadvances.2020001920

2. DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previouslyuntreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216-228.doi:10.1016/S1470-2045(18)30010-X

View original post here:
New ASH Guidelines Highlight a Call to Action for Treatment of Older AML Patients - Targeted Oncology

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17968

Company Profile

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17968

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.

A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17968

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

More:
Induced Pluripotent Stem Cells Market To Grow At 7% YOY In Forecast Years 2026 - The Think Curiouser

With Amy Hess-Fischl RD

It's no secret that people with type 2 diabetes are at an increased risk for major health complications. But one class of medicine might be able to change that, researchers say. According to a recent studypublished in the British Medical Journal (BMJ), a type of medication called SGLT2 inhibitors reduced the risk of heart failure and stroke among patients with type 2 diabetes, suggesting they have cardio-protective benefits.

Otherwise known as sodium glucose co-transporter 2 inhibitors,SGLT2 inhibitorsare a class of medication, delivered in pill form, that can help lower blood glucose levels in diabetic patients.

SGLT2 inhibitors are a relatively new class of medication that can have really impressive results, says Amy Hess-Fischl RD, a certified diabetes educator at the University of Chicago. While most diabetes medications either increase insulin or insulin sensitivity, SGLT2 inhibitors cause the kidneys to excrete glucose into the urine, preventing it from being reabsorbed back into the bloodstream.

By decreasing blood sugar levels, SGLT2 inhibitors can help improve your A1C levels as well, and potentially even aid in medically advised weight loss. According torecent research from Johns Hopkins University, SGLT2 inhibitors typically improve A1C levels anywhere from 0.5% to 1% when taken daily over the course of six months.

Because SGLT2s help decrease sugar in the blood, this also helps reduce some of the complications and long-term damage that can come from having high blood sugar.

Glucose is very attracted to hemoglobin, which is in our red blood cells, says Fischl. The more sugar we have in our blood, the more it can attach to the hemoglobin, and the harder our red blood cells get. Those hard red blood cells, pounding up against our blood vessels for years on end, can cause a lot of damage.

One recent study published in the 2019 issue of theNew England Medical Journal(NEJM) found that the risk of renal failure was 30 percent lower in patients with type 2 diabetes who took the SGLT2 inhibitor Canagliflozin, compared with patients in the control group who took a placebo.

The latest research, published in the September 2020 issue of theBritish Medical Journal(BMJ), reinforces what earlier studies have shown: SGLT2s can protect against heart attack, heart failure, and stroke among patients with type 2 diabetes.

The study authors used five years of healthcare data from type 2 diabetes patients across Canada and the United Kingdom. They surveilled over 200,000 patients who took SGLT2 inhibitors and compared them to the same number of patients who took another class of medication known as DPP-4 inhibitors. (DPP-4s help reduce blood sugar levels in diabetic patients by increasing insulin.) The researchers then recorded any major cardiac events such as heart attack, stroke, and heart failure for an average of 11 months.

The results showed that SGLT2 inhibitors were associated with a lower risk of cardiac events in type 2 diabetics when compared to DPP-4 inhibitors. For example, the rate of heart failure was 3.1 events per 1,000 people among patients who took SGLT2s and 7.7 events per 1,000 people among patients who took DPP-4s. Heart attacks, strokes, and overall mortality rates were also lower in patients who took SGLT2s. These results were consistent across age, sex, past insulin use, and history of cardiovascular disease, the study found.

While the new study produced notable results, it also has some limitations. Observational studies are just that observational, according to Hess-Fischl. They're nice because they give researchers a place to start, but we really need comparative data next.

Additionally, while it may be true that SGLT2s have some cardioprotective benefit, people with type 2 diabetes should be aware that the medication is not without risk.

What we've been finding is that SGLT2s tend to increase the risk of a condition called Euglycemic Diabetic Ketoacidosis, which is a life-threatening condition caused by a buildup of ketones in the bloodstream," Hess-Fischl says. SGLT2s can also cause urinary tract infections particularly in females due to increased sugar being excreted in urine. They are also contraindicated for patients in kidney failure.

All in all, Fischl says, while SGLT2s can be a godsend for some patients with type 2 diabetes, they're far from a miracle drug. More research, such as double-blind placebo studies, is still needed to determine whether or not they can truly guard against cardiac events.

Last updated on 10/20/2020

All About Type 2 Diabetes

Read more from the original source:
SGLT2 Inhibitors Shown to Reduce Risk of Heart Attacks and Strokes in People with Type 2 Diabetes - EndocrineWeb

Dr Masakazu Aihara

Measuring glycated albumin (glycoalbumin, GA) in tears could be a future way for those with diabetes to monitor their blood sugar levels noninvasively.

In a 100-patient trial, levels of GA in tears were found to be strongly correlated (r = .722;P< .001) with those in the blood.

"GA levels in blood are widely measured in clinical practice in Japan," said study investigator Masakazu Aihara, MD, PhD, in an interview.

"It's a biomarker that reflects the 2-week average blood glucose level like fructosamine," explained the researcher from the department of diabetes and metabolic diseases in the Graduate School of Medicine at the University of Tokyo.

This could make it a better biomarker for detecting earlier changes in blood glucose than glycated hemoglobin (HbA1c), which reflects changes in blood glucose over the preceding 2-3 months.

Prior studies had shown that glucose levels can be measured in tear samples and that tear glucose levels correlated with blood glucose levels, Aihara and fellow researchers observed in a poster presentation at the virtual annual meeting of the European Association for the Study of Diabetes.

"While looking for noninvasive diabetes-related markers, we found that tears contained albumin. Based on this fact, we thought that GA could be measured in tears," Aihara explained.

Usingtears to test for biomarkersis not a new idea tears not only protect the eye, they contain a variety of large proteins, and their composition can change with disease. Indeed, researchers have been looking at their usefulness in helping find biomarkers forParkinson's diseaseanddiabetic peripheral neuropathy.

Duringtheir study, Aihara and associates collected tear and blood samples at the same time. Tear samples were assessed using liquid chromatography (LC) and mass spectrometry (MS). An enzymic method was used to measure GA levels in blood. Several diagnosis assay kits for GA are sold in Japan, Aihara said, and at leastone of thesehas U.S. Food and Drug Administration approval.

Multiple regression analysis revealed that the correlation between GA levels in tears and in blood was maintained even after adjustment for age, gender, nephropathy stage, and obesity (P< .001). The results obtained from the tests were thought unlikely to be affected by any changes in the concentration or dilution of tear samples.

"Since GA levels in blood are clinically used in all types of diabetes, GA levels in tears is also expected to be useful in all types of diabetes," Aihara said, noting that the effects of receiving treatment on GA levels in tears is something that he would like to look at.

The team would also like to optimize how tear samples are collected and reduce the volume of tears that are required for analysis. At the moment tears are collected via a dropper and about 100 mcL of tear fluid is required for measurement.

"At present, it is difficult to measure for dry eye patients because sufficient tears cannot be collected, but if the required amount of tears decreases in the future, it may be indicated for dry eye patients," Aihara noted.

Discussing further research plans, he added: "We would like to examine the conditions of LC-MS/MS so that the correlation coefficient with GA in blood can be improved.

"Since LC-MS/MS is a large equipment in the laboratory, I would like to develop a device that can measure at the clinic or at home in the future."

The study was funded by a grant from the Japan Agency for Medical Research and Development. Aihara had no conflicts of interest.

SOURCE:Aihara M et al. EASD 2020,poster presentation 624.

This article originally appeared on MDedge.com, part of the Medscape Professional Network.

Follow this link:
Substance in Tears Could Be Used for Diabetes Monitoring - Medscape

Celiac.com 10/20/2020 - Doctors diagnosing children for type 1 diabetes are increasingly finding other autoimmune conditions that can complicate the outlook for these patients. A team of researchers recently set out to study rates of comorbid autoimmune diseases, including celiac disease, and type 1 diabetes mellitus (T1D) in children.

Rates of type 1 diabetes mellitus (T1D) in children are on the rise, but it's unclear what relationship, if any, this might have with other coexistent autoimmune conditions, since diabetes onset is not well understood.

The team studied 264 boys and 229 girls between 0 and 18 years old with newly diagnosed with T1D in one of the Polish centers from 20102018. They determined diagnoses for related autoimmune illnesses from initial data recorded when patients first received diagnosis for T1D.

The team found that the standardized incidence rate of T1D in children rose 170% over the 9-year study period, while the incidence rate ratio rose 4% per year.

As rates of T1D have risen rapidly in all children of all ages in recent years, so, too have rates of the autoimmune diseases that frequently accompany these conditions. Having an additional autoimmunity disorder is a serious burden for patients with new-onset T1D.

Stay tuned for more information on the challenges faced by children with more than one auto-immune disease.

Read more in Front Endocrinol (Lausanne). 2020; 11: 476.

Reference:Gowiska-Olszewska B, Szabowski M, Panas P, et al. Increasing co-occurance of additional autoimmune disorders at diabetes type 1 onset among children and adolescents diagnosed in years 2010-2018single-center study. Front Endocrinol. Published online August 6, 2020. doi:10.3389/fendo.2020.00476

The research team included Barbara Gowiska-Olszewska,Maciej Szabowski,Patrycja Panas,Karolina oadek,Milena Jamiokowska-Sztabkowska,Anna Justyna Milewska,Anna Kadubiska,Agnieszka Polkowska,Wodzimierz uczyski,and Artur Bossowski. They are variously affiliated with the Department of Pediatrics, Endocrinology, Diabetology With Cardiology Division, Medical University of Bialystok, Biaystok, Poland; the Department of Pediatrics, Rheumatology, Immunology and Metabolic Bone Diseases, Medical University of Bialystok, Biaystok, Poland; the Department of Statistics and Medical Informatics, Medical University of Bialystok, Biaystok, Poland; and the Department of Medical Simulations, Medical University of Bialystok, Biaystok, Poland.

Read the rest here:
Kids with Type 1 Diabetes Increasingly Have Other Autoimmune Diseases - Celiac Disease and Gluten-Free Diet Support - Celiac.com

Know someone with diabetes? Have it yourself? If so, youre not alone.

One in 11 American has diabetes, and one in three has prediabetes.

Managing this disease will help prevent damage to your heart, eyes and nerves over time, says Kristin Bogdonas, a nutrition and wellness educator for University of Illinois Extension.

Bogdonas is offering two Tools to Manage Diabetes workshops in the month of November that will introduce participants to some tools that can help manage carbohydrate intake and plan meals effectively.

One program is online, and the other is in person.

The Tools to Manage Diabetes online program will be 4 to 5 p.m. Tuesday, Nov. 10, via Zoom.

This program is free and offered in conjunction with the Rock Island Public Library.

Once registered, participants will pick up their class materials from the main library, located at 401 19th St., Rock Island.

Class size is limited to 20.

The Tools to Manage Diabetes in-person program will be 1 to 2 p.m. Wednesday, Nov. 11, at the Rock Island County Extension, located at 321 2nd Ave. West, Milan.

There is a $5 cost to attend, and class size is limited to eight persons.

Masks will be required, and social distancing will be practiced.

Space is limited and available on a first-come, first-served basis.

Register through the University of Illinois Extension events page by Monday, Nov. 9.

Participants will receive a diabetes portion plate, carbohydrate counting pocket guide and presentation handouts.

These class materials are funded in part by a City of Rock Island Gaming Grant.

More information about University of Illinois Extension is here.

Go here to see the original:
Need help managing diabetes? A local nutrition and wellness educator is offering guidance - WHBF - OurQuadCities.com

Respondents recognize the importance of tracking their insulin data over time but admit to being too busy and/or forgetting to log their insulin use about eight times within the past month.

Respondents believe technology can help them more effectively manage their condition.

CHICAGO, Oct. 19, 2020 /PRNewswire/ -- The Association of Diabetes Care & Education Specialists (ADCES) today announced the results of a national survey that uncovered people living with diabetes are challenged by tracking information related to their condition over time. The survey found that while 65 percent of respondents report they are doing everything they possibly can to manage their diabetes, just as many (67 percent) feel guilty about not doing a better job. The national survey was supported by Sanofi US.

More than 30 million people have diabetes in the U.S., and for those who take insulin and have been trained on the self-adjustment of doses glucose (blood sugar) readings offer the opportunity to address out-of-range glucose levels. The survey showed that people living with diabetes, who track their insulin use, recognize the importance of looking back at their data over time, but nearly two-thirds agree it would be more helpful if there were better tools for doing it. When citing the most common challenges they have had in tracking their insulin use over a month's time, 62 percent of respondents reported being too busy to log and/or forgetting to log their insulin use.

"The management of diabetes is complex and so deeply personal that people living with diabetes often need to make drastic changes to their lifestyle, relearning their body's needs at the most basic level," said Lorena Drago, MS, RDN, CDN, CDCES and multi-cultural nutrition education expert. "Since the changes people make can impact every area of their lives, I understand why respondents may feel that they are doing all that they can to manage their diabetes, while at the same time still believing they are still not doing enough. The complex nature of managing diabetes presents an opportunity for healthcare professionals to personalize diabetes management. One way to personalize diabetes management is to collect useful diabetes information automatically in one place."

Story continues

Challenges with Tracking Data Over Time & Benefit of Added TechnologyWhile there are several methods available to manage diabetes information, including tracking glucose levels and insulin use, there is still room for improvement. For example:

Among people who track their blood glucose levels with a blood glucose monitor or continuous glucose monitor, 47 percent feel their current method of tracking glucose levels is simple and easy to do, while also wishing it was even more simple and easy to do.

Similarly, among people who currently track their insulin use, 45 percent agree that looking back at their insulin use and how it impacts their glucose levels is easy to do, but they still desire it to be easier.

When considering what could make tracking their diabetes information easier, the survey revealed people living with diabetes wish all their data was put together automatically so they could see everything they need in one place (82 percent). In particular, the vast majority of respondents (more than 80 percent) believe a device which connects to an insulin pen, automatically tracks/records insulin use and wirelessly sends the information to an app on a smartphone or tablet, would be helpful in more effectively managing their diabetes.

"Given the personal nature of diabetes, and the constant management needed, these data truly underscore the challenges people face in tracking and managing diabetes information. These data also show the potential benefits of integrating technology into the care routines of people living with diabetes," said Kellie Antinori-Lent, MSN, RN, ACNS-BC, BC-ADM, CDCES, FADCES and president of ADCES. "My goal as a diabetes care and education specialist is to help overcome the challenges of managing diabetes and it is my belief that tools which automate this process may not only improve the individual's understanding of their condition, but can inform care providers in efficient patient management."

Measuring glucose accurately and logging insulin data is the first step in the wellbeing and care of a person living with diabetes. The potential benefits of a device that automatically brings diabetes data together for people living with diabetes range from having better conversations with their provider and health care team to improving the accuracy of managing or tracking insulin use. Specifically, respondents of the survey living with diabetes would find such a device helpful in:

Giving them a more personalized understanding of their diabetes (79 percent)

Making managing or tracking insulin use less time consuming (78 percent)

Making them feel more empowered when it comes to managing diabetes (75 percent)

"These findings highlight the ongoing need to provide support to people living with diabetes," said Rogelio Braceras, MD, North America Medical Head of General Medicines, Sanofi. "We are proud to be collaborating with ADCES to better understand this population's unmet needs and bring them to the forefront to inform and ultimately help advance personalized care for people living with diabetes."

The national survey was conducted by a market research firm in June and July of 2020 and included more than 700 American adults living with Type 1 or Type 2 diabetes who take insulin. All respondents were taking insulin that was administered with a vial/syringe or pen regularly for at least six months. Respondents were not excluded if they delivered their insulin via an insulin pump or if they also used inhaled insulin.

About the Association of Diabetes Care & Education Specialists: ADCES is an interdisciplinary professional membership organization dedicated to improving prediabetes, diabetes and cardiometabolic care through innovative education, management and support. With more than 12,000 professional members including nurses, dietitians, pharmacists and others, ADCES has a vast network of practitioners working to optimize care and reduce complications. ADCES supports an integrated care model that lowers the cost of care, improves experiences and helps its members lead so better outcomes follow. Learn more at DiabetesEducator.org, or visit us on Facebook or LinkedIn (Association of Diabetes Care & Education Specialists), Twitter (@ADCESdiabetes) and Instagram (@ADCESdiabetes).

About Sanofi:Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Contact:Matt Eaton, 312-601-4866, meaton@adces.org

View original content to download multimedia:http://www.prnewswire.com/news-releases/national-survey-reveals-people-living-with-diabetes-feel-they-are-doing-everything-they-can-to-manage-their-condition-yet-believe-more-can-be-done-301154175.html

SOURCE Association of Diabetes Care & Education Specialists

Here is the original post:
National Survey Reveals People Living with Diabetes Feel They Are Doing Everything They Can to Manage Their Condition, Yet Believe More Can Be Done -...

BERLIN Coos County Family Health Services has begun offering specialized support services to people living with diabetes.

Heather Beaudry, RN, will lead this new program as part of her work as a certified diabetes care and support specialist. The program is newly accredited by the Association of Diabetes Care & Education Specialists, and is available to all Coos County Family Health Servicespatients.

Our mission is to help people living with diabetes gain control of their illness, and live full and active lives, said Beaudry. Diabetes is a chronic illness that poses many challenges. We can help people with the skills and knowledge they need to improve their health.

The program will be offered at the organizations Pleasant Street Clinic on Monday through Thursday, from 8 a.m.-5 p.m. The service is covered by most insurances, and can be provided on a discounted basis for those in need. Diabetes education is a covered Medicare benefit when delivered through an accredited program.

Diabetes is one of the most common and significant illnesses affecting older adults in our community, said Patty Couture, Coos County Family Health Serviceschief operating officer.

Diabetes education services utilize a collaborative process through which people with diabetes work with a Certified Diabetes Care and Education Specialist to receive individualized care to help them reach their health goals.

Programs like the one we have established can help people with diabetes improve their health and to live long and productive lives, said Beaudry.

For more information about the program, or to schedule a time to meet with Heather Beaudry, contact any of the Family Health Clinics or call (603) 752-2040.

Go here to read the rest:
Coos Family Health to offer specialized support to those living with Diabetes - Berlindailysun

IndustryGrowthInsights (IGI), a prominent market research firm in its own industry, has published a detailed report on Global Diabetes Treatment Market. This market research report provides comprehensive and in-depth analysis on the market which can possibly help an enterprise to identify lucrative opportunities and assist them with fabricating creative business strategies. The market report provides information about the current market scenario regarding the global supply and demand, key market trends and opportunities in the market, and challenges and threats faced by the industry players.

The Diabetes Treatment market report talks about the competitive scenario among the industry players and imparts aspiring and emerging industry players with the future market insights in a detailed manner. This market report includes crucial data and figures which are structured out in a concise yet understandable manner. The research report covers the updates on the government regulations and policies which illustrates key opportunities and challenges of the market. IndustryGrowthInsights (IGI) has been monitoring the market since few years and collaborated with eminent players of the industry to give better insights on the market. It has conducted vigorous research and implied robust methodology to provide accurate predictions about the market.

You can buy the complete report on @ https://industrygrowthinsights.com/checkout/?reportId=186783

Impacts of Advancements and COVID-19 on the market.

Amidst the COVID-19, few segments of the market have witnessed a disruption due to the gap in supply and demand which has impacted the growth of the Diabetes Treatment market. Along with this, the latest advancements have changed the market dynamics of the market. This research report covers the wide-range analysis of the COVID-19 impact to the industry and gives out insights on the change in the market scenario due to the advancements.

Get Exclusive Free Sample Report @ https://industrygrowthinsights.com/request-sample/?reportId=186783

Market Segmentation

Some of the major companies that are covered in the report.

Novo NordiskBayerTeva Pharmaceuticals Pvt Ltd.MerckCompany Inc.Medtronic Inc.JohnsonJohnsonHome Diagnostics Inc.Amylin Pharmaceuticals Inc.Abbott Laboratories

Note: Additional companies

Based on the type, the market is segmented into

InsulinOral Hypoglycaemic DrugsNon-Insulin Injectable Drugs

Based on the application, the market is segregated into

HospitalPersonal UseClinic

Based on the geographical location, the market is segregated into

Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

IndustryGrowthInsights (IGI) provides yearly updates on the Diabetes Treatment market that assist the clients to stay ahead in the competitive space.

Why one should buy this Diabetes Treatment Report?

The market research report provides all valuable constituents of the market such as revenue growth, product pricing & analysis, growth potential, and guidelines to tackle the challenges in the market. The report covers all the crucial mergers & acquisitions, partnerships, and collaborations that created further created opportunities or in some cases, challenges for the industry players.

This report includes latest product news, advancements, and updates from the prominent player of the industry that has leveraged their position in the market. It also provides business strategies implemented by the key players and yardstick to arrive on informed business decisions. Moreover, it gives insights on the consumer behavior patterns that can help the enterprise to curate the business strategies accordingly.

IndustryGrowthInsights (IGI) bestows the clients with the specialized customized options related to the regional analysis, company analysis, and product analysis, among others.

Complete Table Content of the Market

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Diabetes Treatment Market Overview

Diabetes Treatment Supply Chain Analysis

Diabetes Treatment Pricing Analysis

Global Diabetes Treatment Market Analysis and Forecast by Type

Global Diabetes Treatment Market Analysis and Forecast by Application

Global Diabetes Treatment Market Analysis and Forecast by Sales Channel

Global Diabetes Treatment Market Analysis and Forecast by Region

North America Diabetes Treatment Market Analysis and Forecast

Latin America Diabetes Treatment Market Analysis and Forecast

Europe Diabetes Treatment Market Analysis and Forecast

Asia Pacific Diabetes Treatment Market Analysis and Forecast

Middle East & Africa Diabetes Treatment Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, please reach out to us @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=186783

About the Company

IndustryGrowthInsights (IGI) is the largest aggregator of the market research report in the industry with more than 800 global clients. The company has extensively invested in the research analysts training and programs to keep the analyst tapped with the best industry standards and provide the clients with the&utmost experience. Our dedicated team has been collaborating with the industry experts to give out the precise data and figures related to the industry. It conducts primary research, secondary research, and consumer surveys to provide an in-depth analysis of the market. The market research firm has worked in several business verticals and has been successful to earn high credentials over the time.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://industrygrowthinsights.com

Continue reading here:
Growth Of Diabetes Treatment Market In Global Industry: Overview, Size And Share 2020-2027 - The Think Curiouser

As a public service, Shaw Media will provide open access to information related to the COVID-19 (Coronavirus) emergency. Sign up for the newsletter here

Dr. Tiffany E. Groen likened learning about the coronavirus as running across a bridge while trying to build it.

Its amazing how differently the virus affects people, Groen said. It might give one person respiratory issues. Another person might have no respiratory issues but have blood clots.

But one thing appears clear. Having diabetes is a risk factor for severe COVID-19.

People with diabetes arent necessarily more at catching the virus, according to the American Diabetes Association.

But they do have increased risk for severe complications, especially if they have other conditions, too, such as heart disease, the ADA said.

There is not enough evidence that having diabetes will increase the risk of contracting the virus, Dr. Babak Pazooki, an endocrinologist with AMITA Health Saint Joseph Medical Center in Joliet, said. But there is enough evidence to support the notion that if you have diabetes, your outcome may be worse.

In fact, diabetics are at risk of complications when they contract any virus, the ADA said.

Diabetics are also at greater risk of acquiring and having worse outcomes certain infections, such as urinary tract and respiratory infections, Pazooki said

Groen said diabetes, especially diabetes that isnt well-controlled, can cause inflammation. This may lead to complications in times of illness.

When a diabetic gets sick with any illness, the tendency is for the blood sugar to be elevated, Groen said. The immune system doesnt work as well, and it cant fight it [the illness] very well.

Jan Smith of Joliet saw that firsthand with her husband James V. Smith, who was diagnosed with type 2 diabetes about five years ago. He kept it under good control until he caught the coronavirus, she said.

Jan feels her husbands lack of appetite during his illness might have affected his blood sugar control. She said James was treated in an emergency department on Aug. 31, but his condition continued to worsen.

He went into the hospital on Sept. 8, Jan said. and he died on Sept. 23.

Pazooki said diabetes becomes difficult to manage once the patient becomes severely ill.

In July, the Centers for Disease Control and Prevention published a study of 10,000 people who died from the virus, which further showed the connection between diabetes and COVID-19.

The study found that 49.6% of those aged 65 and up had diabetes as did 35% of those younger than age 65. When compared to people who were white more Hispanic and non-white people were older than 65, the CDC study also said.

But generally speaking, diabetes is more common in people of color and the complications and outcomes are worse, for whatever the reasons might be, Pazooki said.

The CDC study also said more studies are needed to clarify some of the associations, such as those among age, race/ethnicity, SARS-CoV-2 infection, disease severity, underlying medical conditions (especially diabetes) poverty and access to health care and the ability to comply with mitigation recommendations while maintaining essential work responsibilities.

Groen said the longstanding health and social inequities in the U.S. increases the risk in some minority groups, who often have additional chronic conditions, too, such as obesity and high blood pressure.

On top of that, not all types of diabetes are the same and its unclear if the risks are the same.

Certainly high blood sugar plays a role in all forms of diabetes, she said.

A study published April 15 in the Journal of Medical Virology suggests that blood sugars that remain high over time might contribute to the severity of COVID-19 in some people with diabetes.

Pregnant women are also more prone to blood clots, Groen said. In some cases, the SARS-CoV-2 virus also causes blood clots, she added.

What might make Type 2 diabetes particularly troublesome in terms of covid is that it often involves multiple other factors: metabolic syndrome, obesity and even genetics, Pazooki said.

So it is possible that those are other conditions that leads to the type 2 diabetes being more of a bigger risk factor for having adverse outcomes, Pazooki said.

But even treating the coronavirus in a diabetic patient is tricky, Groen said.

If they need steroids, that can elevate the blood sugar, she said.

A study published July 17 in The Lancet said these blood sugar elevations can become quite high, along with an increase insulin resistance, when steroids are administered to a diabetic patient.

Pazooki said diabetics who dont normally take insulin might have their oral diabetes medication temporarily stopped and then switched to insulin if they are being treated for COVID-19 in the hospital.

Oral medication might be harmful if the patient has abnormal kidney function, needs to fast for tests, or has an irregular meal schedule, Pazooki said.

But often this change in treating the diabetes is temporary.

The majority of patients go back home on the medications they came to the hospital with, Pazooki said.

So whats a diabetic to do?

Pazooki suggests diabetics work with their health care providers to keep their condition controlled. Eat a healthy diet, get regular exercise, he said.

Then, hypothetically, outcomes from COVID-19 might be better, he said.

We dont have strong evidence in terms of COVID-19, Pazooki said. But we do have strong evidence in terms of all other types of infectionand COVID-19 is just another infection.

See more here:
Diabetes may not increase your risk of catching the coronavirus - The Herald-News

Six Texas A&M engineering and medical students came together to develop tools to more effectively diagnose diabetic retinopathy.

Texas A&M Engineering

About 10% of the U.S. population has diabetes, and about a third of that number, around 11 million people, will suffer from diabetic retinopathy diabetes-induced irreversible vision loss, at some point in their lifetime. People in both rural and underserved communities may suffer more because they dont have access to specialists, and its likely the disease is underdiagnosed.

Ai-Ris (pronounced A-Iris), a team comprised of six engineering and medical students from Texas A&M University, are working to address these diagnosis barriers. Specifically, they are designing a tool to better reach individuals in rural or underserved communities.

Were developing this system that leverages machine learning and also uses low-cost hardware in a user-friendly form, something like a headset that can be used in a non-clinical setting and doesnt require the presence of an optometrist or ophthalmologist, said T.J. Falohun, team member and biomedical engineering doctoral student.

Uthej Vattipalli, civil engineering graduate student, has personally witnessed the impact of diabetic retinopathy. His grandfather began to lose his eyesight after retirement, but could not afford to get a diagnosis. Vattipalli said the teams work could transform the health care market.

We are going to need an army to go into what we want to do if we want that impact, Vattipalli said. Not everybody has all the skill in the world. Theres definitely been complementary skill sets required to get tasks accomplished. One of the good things of being on an interdisciplinary team is the variety of skill sets that help you keep moving forward.

The project started as a Sling Health initiative.Sling Health National Networkis a student-run biotechnology incubator that provides resources, training and mentorship to teams of students in engineering, medicine and business tackling clinical problems by developing innovative solutions.

The project began to gain members and motivation and spread outside of Sling Health into its entrepreneurship effort. The team continued its work with the help of the Engineering Incubator at Texas A&M, where the students worked with Rodney Boehm, director of Engineering Entrepreneurship, to expand their access to resources.

Now a limited liability company, Ai-Ris placed second in the 2020 Sling Health Demo Day and participated in the Innovation Corps Site Fellows program at Texas A&M. The team also recently won a VentureWell E-team Grant. Through VentureWell, the team will receive funding, connections and training to further their entrepreneurial efforts.

Amir Tofighi Zavareh 19, an electrical engineering doctoral graduate, said beyond making an impact, he joined the team because he is intrigued by the technical challenges involved. He said collecting the retinal images at a low cost is a challenge that is not being addressed in the market.

Right now in the clinics, they use this benchtop device that costs tens of thousands of dollars. Its a very tricky thing to do, Tofighi Zavareh said. We want to do that with low-cost devices, so thats going to make it challenging to do that at the same quality levels but at lower costs so it can be available to rural areas.

Harsha Mohan, a former student and current graduate student studying robotics at Johns Hopkins University, said working on a multidisciplinary team has taught members soft skills such as communicating effectively and elevating each members strengths.

We have people from all over the world; we have people from different backgrounds, and to work toward health care equity at this point of my life, Im not sure theres anything better than this, Mohan said.

Saurabh Biswas, principal investigator of VentureWell Grant and faculty advisor of Sling Health, said Ai-Ris is a great example of a highly motivated team with complementary skill sets, which Biswas said is critical to solve problems in health care.

I truly hope otherAggie innovators will follow their example and take advantage of great programs like VentureWell Grants, Sling Health andNSF I-site and I-Corpto bring their ideas from concept to prototype with extensive customerdiscovery to validate product-market fit, said Biswas, who also serves as executive director of TEES Commercialization and Entrepreneurship and as a professor of practicein the Department of Biomedical Engineering.

While the team continues to delve into the world of entrepreneurship and health care integration, the students are already seeing how their work can play a part in treating many ocular diseases in the future. Marcus Deayala, a biotechnology graduate student, said he is excited to play a part in breaking down barriers to AI diagnostics, which he says will shape the landscape of health care in the future.

I think we all understand that in the richest country (in the world), this many people going blind by a completely avoidable disease is ridiculous, Deayala said. If the level of health care is going to increase, the cost has to come down. We have to become more efficient and devices like these have to be instituted in one way or another.

The rest is here:
Combating Diabetes-Induced Blindness - Texas A&M Today - Texas A&M University Today